SCOTTSDALE, Ariz. and GAITHERSBERG, Md., May 31, 2016 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc. (“Avant”) (OTCQB:AVDX), an innovative molecular diagnostics company,
today announced that Company representatives will be presenting at the following upcoming investor conferences:
SeeThru Equity MicroCap Conference
Where: Convene Conference Center, 730 Third Avenue, New York City, NY
When: Tuesday, May 31st, 2016 at 3pm
Marcum MicroCap Conference
Where: Grand Hyatt Hotel, 109 East 42nd St, New York, NY
When: Wednesday, June 1st, 2016 at 2:30pm
LD Micro Invitational Conference
Where: Luxe Sunset Bel Air Hotel, Los Angeles, CA
When: Wednesday, June 8, 2016 3:30pm
About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in biomarker tests that are being developed in the areas of
oncology and neurology. Avant provides personalized medicine diagnostic testing capabilities through its TheraLink® Diagnostic
Assays, primarily for breast cancer, to assist clinical oncologists in identify likely responders for roughly 30 FDA-approved drug
treatment regimens through its CLIA/CAP. Avant is the leading developer of proteomic technologies for measuring the activation
status of key signaling pathways across several different cancer types, including breast, ovarian and pancreatic that are
instrumental in the development of companion diagnostics for molecular-targeted therapies. Avant has used these proteomic
technologies to support the drug development programs of many of the top biopharmaceutical companies in the world. For more
information please visit www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is
a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian
tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and
stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and
ovarian adenocarcinoma.
Avant’s neurology division owns the rights to MSPrecise™, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an
exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test™for Alzheimer's disease, which was developed by Prof.
Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease
(NuroPro).
For further information please visit www.AvantDiagnostics.com, or connect with the Company on Facebook and LinkedIn.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast,"
"estimated" and "intend," among others. These forward-looking statements are based on Avant's current expectations and actual
results could differ materially. There are a number of factors that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical
trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to
obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking
statement except as required by law. Investors should read the risk factors set forth in Avant's Form 10-K filed with the
Securities and Exchange Commission on January 13, 2016, and other periodic reports filed with the Securities and Exchange
Commission.
Investor and Media Contact: Ascendant Partners, LLC Fred Sommer 732-410-9810 fred@ascendantpartnersllc.com
